Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2016 | 12-2015 | 12-2014 | 12-2013 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -888 | -5,400 | 3,530 | -5,540 |
| Depreciation Amortization | 57 | 270 | 300 | 580 |
| Accounts receivable | 35 | N/A | N/A | N/A |
| Other Working Capital | -1,190 | -6,530 | 9,260 | -1,240 |
| Other Operating Activity | -70 | 2,000 | 1,510 | 410 |
| Operating Cash Flow | $-2,056 | $-9,660 | $14,600 | $-5,790 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -35 | -230 | -140 | -30 |
| Investing Cash Flow | $-35 | $-230 | $-140 | $-30 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 9 | N/A | N/A | N/A |
| Common Stock Repurchased | -1 | N/A | N/A | N/A |
| Other Financing Activity | -283 | 39,400 | 4,910 | 1,960 |
| Financing Cash Flow | $-275 | $39,400 | $4,910 | $1,960 |
| Beginning Cash Position | 51,744 | 22,180 | 2,810 | 6,670 |
| End Cash Position | 49,378 | 51,680 | 22,180 | 2,810 |
| Net Cash Flow | $-2,366 | $29,490 | $19,370 | $-3,860 |
| Free Cash Flow | ||||
| Operating Cash Flow | -2,056 | -9,660 | 14,600 | -5,790 |
| Capital Expenditure | -35 | N/A | N/A | N/A |
| Free Cash Flow | -2,091 | -9,660 | 14,600 | -5,790 |